Please assess the completion status of the following clinical trial:

Trial Title: Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with known Paroxysmal Nocturnal Haemoglobinuria (PNH)~* LDH \>=1.5 Upper Limit of Normal (ULN)~* Resistance to Eculizumab proven by both a recognised C5 polymorphism on genetic screening and complement inhibition on CH50 ELISA of \<100% at concentrations of Eculizumab in excess of 50 μg/mL~* Willing to self-inject Coversin daily or to receive daily subcutaneous injections by a home nurse or in a doctor's office or hospital clinic~* Males or females taking adequate contraceptive precautions if of childbearing potential, 18 - 80 years of age~* Body weight ≥50kg and ≤ 100kg~* The patient has provided written informed consent.~* Willing to avoid prohibited medications for duration of study~* Must agree to take appropriate prophylactic precautions against Neisseria infection.~* Must be counselled regarding the possible reproductive risks of using Coversin and be advised to use an adequate method of contraception pending further data on reproductive toxicology.~Exclusion Criteria:~* Body weight \<50kg or\>100kg~* Pregnancy (females)~* Failure to satisfy the PI of fitness to participate for any other reason~* Known allergy to ticks or severe reaction to arthropod venom (e.g., bee or wasp venom)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Coversin (Nomacopan) (Type: OTHER): This is an open label, non-comparator study.~Patient will be given a single ablating dose of 0.57mg/kg per subject followed by daily repeat maintenance doses. The initial repeat dose will be 25% of the ablating dose. If this is insufficient to maintain complement inhibition at ≤10% of baseline (pre-treatment) level after 5 days of treatment the daily dose will be increased by doubling until that level of inhibition is achieved. In the event of 100% inhibition being achieved the dose may be titrated downwards at the PI's discretion until a satisfactory clinical result is obtained. If at any point in treatment complement inhibition falls to less than 50% of baseline a further ablating dose of 0.57mg/kg should be given. Coversin lyophilised powder in each vial was diluted with 0.6 mL water for injection prior to use.

Based on this trial design, predict the completion outcome and termination type (if applicable).